Skip to main content
Clinical Trials/NCT06178835
NCT06178835
Completed
Phase 4

Erythropoietin for the Prevention of Postoperative Delirium in Elderly Patients Undergoing Total Joint Arthroplasty: Randomized Controlled Study

Yonsei University1 site in 1 country76 target enrollmentSeptember 12, 2017

Overview

Phase
Phase 4
Intervention
Erythropoietin
Conditions
Postoperative Delirium
Sponsor
Yonsei University
Enrollment
76
Locations
1
Primary Endpoint
Incidence of delirium
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Postoperative delirium is a common complication after surgery. The underlying pathophysiology of this complication is unclear, however neuroinflammation and oxidative stress secondary to surgery had shown to be the cause of postoperative cognitive dysfunction and delirium. Erythropoietin represents non-erythropoietic effects of anti-inflammatory properties. The aims of this study were to determine the role of erythropoietin toward the development of postoperative delirium, in terms of changes in inflammatory reaction by affecting the innate immunity in elderly patients undergoing total joint arthroplasty surgery.

Registry
clinicaltrials.gov
Start Date
September 12, 2017
End Date
August 28, 2019
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 65 years and older
  • Patients scheduled for elective total knee arthroplasty, total hip arthroplasty

Exclusion Criteria

  • Unable to communicate
  • Cognitive impairment
  • Unable to pre-screen delirium due to underlying central nervous system disease
  • History of hypersensitivity related to erythropoietin and other anesthesia-related drugs
  • History of myocardial infarction, pulmonary infarction, cerebral infarction, ischemic vascular disease, epilpesy, chronic liver disease, chronic kidney disease
  • Uncontrolled high blood pressure
  • Within one month of starting anti-hypertensive medication

Arms & Interventions

Erythropoietin

500 IU/kg of EPO given intramuscularly 3 times for each patient

Intervention: Erythropoietin

Control

Same amount of normal saline given intramuscularly 3 times for each patient

Intervention: normal saline

Outcomes

Primary Outcomes

Incidence of delirium

Time Frame: 2 days post surgery, 5 days post surgery

Development of postoperative delirium determined by validated evaluation tests.

Secondary Outcomes

  • Inflammatory biomarker(before surgery, after surgery, 3 days post surgery day 3)

Study Sites (1)

Loading locations...

Similar Trials